{"name":"Ventyx Biosciences, Inc.","slug":"ventyx","ticker":"VTYX","exchange":"NASDAQ","domain":"ventyxbio.com","description":"Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases. The company's lead product candidate, VTX958, is being investigated for the treatment of psoriasis and other autoimmune conditions. Ventyx Biosciences has a strong pipeline and is working to bring innovative treatments to patients in need.","hq":"Encinitas, CA","founded":0,"employees":"","ceo":"Tassos Gianakakos","sector":"Autoimmune / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$680M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"VTX958 patent cliff ($0.00 at risk)","drug":"VTX958","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Ventyx Biosciences Announces FDA Fast Track Designation for VTX958","summary":"Ventyx Biosciences announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VTX958 for the treatment of moderate to severe plaque psoriasis.","drugName":"VTX958","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Ventyx Biosciences Reports Third Quarter 2023 Financial Results","summary":"Ventyx Biosciences reported its financial results for the third quarter of 2023, highlighting progress in its clinical programs and pipeline development.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1iaWxMNkhEZlZncjQ2dzJqM0JlREhybHA0c1VJNWR0OFVxalhuYjhHbWFsX205ZFdxeHNseWlBXzVGdUlXZ3Jkc2lmS2JhSGQ5MXJTZ2ZjVWZGUEtJYlZRMUlSYjJvcVFHeUM5eUtR?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Ventyx Biosciences, Inc. (VTYX) - Stock Titan","headline":"If You Invested $1,000 in Ventyx Biosciences, Inc. (VTYX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPaE1EUi1rMGJtdk1VbUxjakpLQmZqeDNnWExvTkc2cWtXSjJBQVFuMndNRXpHVVFGRUdHUmFfYTI5dWhLbTVDNl9nUEtHZHpDVlc2bmJ3LVJIUmcxcnVuUWdlNHFqUnVHNklBX2NGYkNjV1ZaNTViOVI4eXhYYUhDRFYxVndDZjBmY2VjSDdnQTFYQm9OaG1PdWhRaw?oc=5","date":"2026-01-19","type":"pipeline","source":"San Diego Business Journal","summary":"Eli Lilly Snaps Up Ventyx Biosciences - San Diego Business Journal","headline":"Eli Lilly Snaps Up Ventyx Biosciences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQWGxPTnZ1NEtpdVRFNTdpdW5PTnZlX2hVaDZSMHhjQVRqbUlqU3JzTnlHT214RU9ZZXVGUXBDQW84aTZSZ3ktOERyMHUtdFViakRiMFBtZjY3WXhPQnlUUUtFRVdKRFhDRnR1bnkzdC1nZzA0dUxlWG10TFNPTTRvQmN0N2V2NkJ3QVZOVDRhVk85TGFjR29MZHJ0S1FSRXE3MGZzNWVqUk9GdjhWRmtNSw?oc=5","date":"2026-01-08","type":"pipeline","source":"MedCity News","summary":"Eli Lilly Boosts Its Immunology Drug Pipeline With $1.2B Ventyx Bio Acquisition - MedCity News","headline":"Eli Lilly Boosts Its Immunology Drug Pipeline With $1.2B Ventyx Bio Acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQYjdwYWFSNE1WN3JMRkFzUnk5NGk4cWo3N05TMGhrdHphaFJDajVYeUZDRnR3TG43Q0ZXUm1lZXN6QXM4LURmWldsX1NkaWgyY3R5VWpjd2Z4RmZOY1ZuZWZ3NjNYLUVYUm5NdHg0dFVURlpMbnY1dU5mUVJtV0lOLUVlNEk2U0RDMklxSXNrcEVIUW8yUWNYeE05TUZQOWhVMXhvaFZfaWdwbXJYUlVOUGZ4Z2h3UXA5?oc=5","date":"2026-01-07","type":"deal","source":"Eli Lilly","summary":"Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases - Eli Lilly","headline":"Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNMXFzOEV1bmZrbHlHb2RQQ25TM29rSFdXRnZhNEFlcnpsS3lTYWVhZnJZd3BwdXRPeldJV182c0c5X1Q3LUo3UXZjZnAtYkdYUzV1MnJTX3FBdjROYzhrSl96NFJXR1dyTFUxT09fY3NkNDk4d0hWYW1Rc2JXc0o0dEo4WDlhTXBVY0E?oc=5","date":"2026-01-07","type":"deal","source":"WSJ","summary":"Exclusive | Eli Lilly Nears Deal for Biotech Ventyx - WSJ","headline":"Exclusive | Eli Lilly Nears Deal for Biotech Ventyx","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxNTW9fc3pWS2QybTBOZTA2QldSOF95V09TdkJkbUZlNXpmU3A5R3UtSmtHWXpUY2pBY1lRa2hfSlJER2xlbG8zZnZEM1czOXJvQVZ1SFNTS0VReXZMNFRnWmlvVExSUVZsUkpTZE5wMy1QUWlweVN4a2QtVVhQWUpTYTM3bXh2TmZKbDZzUHZPTnZkdlBxSkg4aHNSX29VNGNtNHB2S2dGcWpZNTN0NmVRbVFMWFdnOEJEMUdzSE9mZ1EwaWxJMWEtYzl1ZV82dW9TNzJMZzBOd2x2WUU?oc=5","date":"2026-01-06","type":"deal","source":"Reuters","summary":"Lilly in talks to buy Ventyx Biosciences for more than $1 billion, WSJ reports - Reuters","headline":"Lilly in talks to buy Ventyx Biosciences for more than $1 billion, WSJ reports","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxPTzBMR1Nlc3RLYlZQR044eEl5cE1YWlFxcUNISGVKakNMMkxaR1BBamRwMEZTVHJrVG82UFBzMWZNRUVpQzJRVVoxcmZmaTJIekVYNnp1dWp6NmhUYnA0SGlHbUNVaGZnaXVtMXd4Q18wNXQ3VXFqRVRqV1lDSnJiTDNyRFg2UXpyU3JrdjJvTXdfMWFsVlB0eGJHal9ZemwzVG5HX256S2pReGJ5cDNINS1kWXJzenB6amhOUkY2WFJ3VEdMS3c?oc=5","date":"2026-01-06","type":"pipeline","source":"Investing.com","summary":"Ventyx Biosciences stock surges after Eli Lilly acquisition talks - Investing.com","headline":"Ventyx Biosciences stock surges after Eli Lilly acquisition talks","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-02","type":"earnings","source":"simplywall.st","summary":"Institutional owners may ignore Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) recent US$77m market cap decline as longer-term profits stay in the green - simplywall.st","headline":"Institutional owners may ignore Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) recent US$77m market cap decline as longer-term","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNZU50WWp1c0VZbS1ndGwtMmVIQUV4U0Y2cmpVaUU4X3F3U0U4Y3dzd2l6UFRkWmRFbGJjdHRDT3hhQU5kQTFsdi1uMWkxT2haRThaRXlfUUkweU9ERDRFMzVOOVFiMFpCc3NFVnpNZU50RGxEcHNHaW5VQnVHSmlSWmFLU1g4T3NQV0gza1BBbXNHcGwzVkNlVFk4N3V5cE5GOTRxT3R4LURRZkE1SnlWVDFjWklhLUh1VzVUdHJRdUdTUQ?oc=5","date":"2025-10-23","type":"trial","source":"MedCity News","summary":"Ventyx Bio Cardiovascular Drug’s Phase 2 Results Set Up Talks With a Big Pharma Firm - MedCity News","headline":"Ventyx Bio Cardiovascular Drug’s Phase 2 Results Set Up Talks With a Big Pharma Firm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQQnMzZWF5ZkwzRm1ELUF2QWJnSGpQU3g3QXBiTzA1SHRBaklpMVJya3czNW9QeHpoYkRSY1ZPWFpBbjhVWWpSdllhMU5QVFNraVI4cVo2OU5VNk96LW0tWmhTRzRUR3RQd1dLVHVRX1dkeVViTHdfMVV1amNDSHd6YldUOV9QQVBUaEZHMzFqeF84NVE0REhIX213MlYyY09yMnZnZTFEZXRGMk5SaXVQNmtCdlppQl8x?oc=5","date":"2025-10-23","type":"trial","source":"Seeking Alpha","summary":"Ventyx Biosciences: At Last, A Data Win In CV - But Clarity On Next Steps Needed (VTYX) - Seeking Alpha","headline":"Ventyx Biosciences: At Last, A Data Win In CV - But Clarity On Next Steps Needed (VTYX)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-23","type":"pipeline","source":"simplywall.st","summary":"Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Deliver On Growth Plans? - simplywall.st","headline":"Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Deliver On Growth Plans?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE5sQzhOT09JaE1WcGgzRTFkOUdjYU9HN2pfSm5kaWludXpaZXlxN3U3ZDRQRVdsb1NMclR4NFl2aXJ4c3ptbkpkVlFfeG9XREY2N2lLa2t6LXdEdXFZSGc1aHpIUjRMWDl2?oc=5","date":"2025-07-09","type":"regulatory","source":"MarketBeat","summary":"Ventyx Biosciences (VTYX) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat","headline":"Ventyx Biosciences (VTYX) FDA Approvals, PDUFA Dates & Drug Alerts 2026","sentiment":"positive"}],"patents":[{"drugName":"VTX958","drugSlug":"generic-name-not-publicly-disclosed","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Celgene Corporation","Gilead Sciences, Inc.","Regeneron Pharmaceuticals, Inc."],"therapeuticFocus":["Autoimmune Diseases"],"financials":null,"yahoo":null}